Valuation : Fate Therapeutics, Inc.

Market Cap 291M 251M 235M 215M 404M 27.7B 407M 2.79B 1.09B 14.05B 1.09B 1.07B 46.52B P/E 2026 *
-2.28x
P/E 2027 * -2.35x
Enterprise Value 291M 251M 235M 215M 404M 27.7B 407M 2.79B 1.09B 14.05B 1.09B 1.07B 46.52B EV / Sales 2026 *
51.5x
EV / Sales 2027 * 61.1x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day-2.26%
1 week-2.66%
Current month-3.06%
1 month-3.06%
3 months-13.32%
6 months+73.36%
Current year+141.71%
1 week 2.36
Extreme 2.365
2.62
1 month 2.23
Extreme 2.23
2.88
Current year 0.97
Extreme 0.97
3.23
1 year 0.93
Extreme 0.9335
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
76.42
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
4/8/26 Sell

Chief Executive Officer

-43,947 0.0377%
4/8/26 Sell

Compliance Officer

-38,800 0.0333%
12/6/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
-2.26%-2.66%+130.58%-5.38% 291M
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+1.59%-2.89%-17.14%+450.02% 25.89B
-0.95%-10.27%+0.61%-16.29% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
-0.27%-0.20%+46.42%+143.14% 13.49B
Average -2.40%-2.90%+58.66%+164.78% 28.22B
Weighted average by Cap. -2.20%-3.49%+48.01%+144.75%

Financials

2026 *2027 *
Net sales 5.65M 4.86M 4.57M 4.17M 7.83M 538M 7.89M 54.12M 21.06M 273M 21.21M 20.75M 903M 4.77M 4.1M 3.85M 3.52M 6.61M 454M 6.66M 45.66M 17.77M 230M 17.9M 17.51M 761M
Net income -129M -111M -104M -95.07M -179M -12.26B -180M -1.23B -480M -6.22B -484M -473M -20.58B -146M -126M -118M -108M -202M -13.89B -204M -1.4B -544M -7.05B -548M -536M -23.33B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
01/09/26 USD 2.375 -2.26% 275,127
28/08/26 USD 2.430 -4.33% 714,904
27/08/26 USD 2.540 -1.17% 1,574,944
26/08/26 USD 2.570 +0.78% 1,050,526
25/08/26 USD 2.550 +4.51% 2,439,393
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2.430USD
Average target price
5.744USD
Spread / Average Target
+136.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock